Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
25 hedge funds and large institutions have $76.8M invested in Sinovac Biotech, Ltd in 2019 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 4 closing their positions.
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
7% less funds holding
Funds holding: 27 → 25 (-2)
8% less capital invested
Capital invested by funds: $83.7M → $76.8M (-$6.89M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$127K |
| 2 |
RQS
Ramsey Quantitative Systems
Louisville,
Kentucky
|
+$72.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$10.1K |
| 4 |
AG
Advisor Group
Phoenix,
Arizona
|
+$8.95K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
+$585 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FIM
Freedom Investment Management
Hartford,
Connecticut
|
-$137K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$92K |
| 3 |
Renaissance Technologies
New York
|
-$83.7K |
| 4 |
Morgan Stanley
New York
|
-$47K |
| 5 |
NA
Navellier & Associates
Reno,
Nevada
|
-$11.6K |
SVA Hedge Fund Activity: Q1 2019 in Review
25 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2019, worth a combined $76.8M — down 8.2% from $83.7M a quarter earlier.
Fund positioning in SVA was balanced in Q1 2019: 4 funds opened new positions, 4 closed out, 4 added to existing stakes and 7 trimmed.
The largest buyer was State Street, adding an estimated $127K. The largest seller was Freedom Investment Management, cutting an estimated $137K.
- 25 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2019, down from 27 in Q4 2018.
- Funds reported $76.8M of Sinovac Biotech, Ltd stock for Q1 2019, down 8.2% quarter-over-quarter.
- 4 funds opened new Sinovac Biotech, Ltd positions in Q1 2019 and 4 closed out, a net change of 0 holders.
- The largest Sinovac Biotech, Ltd buyer in Q1 2019 was State Street, an estimated $127K added.
- The largest Sinovac Biotech, Ltd seller in Q1 2019 was Freedom Investment Management, an estimated $137K sold.
Based on aggregated 13F filings for Q1 2019.